WSJ
19 Aug 2026, 20:17 UTC · 9w ago
Bond Yields Dive After Treasury Increases Buybacks
Impact · against what's priced in
Moderna and Merck are likely to see valuation increases following positive mRNA cancer vaccine trial results. As this data targets a high-addressable market and provides new clinical validation, it represents a material catalyst for both companies.
- MRNA+0.80
No priced-in read yet
- In context
Clinical success in mRNA cancer vaccines validates the company's platform expansion beyond respiratory vaccines.
Read from the article alone
Top 2 movers · tap to explore
